BioSpace News Archive

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported financial results for the three months ended March 31, 2024, and provided a business update.

MEI Pharma, Inc., a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, announced that it filed a Form 15 with the Securities and Exchange Commission to deregister its common stock under Section 12 of the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations under Section 15 of the Exchange Act.

AnaptysBio, Inc. announced positive top-line results from its global GEMINI-1 and GEMINI-2 Phase 3 trials evaluating the safety and efficacy of investigational imsidolimab in patients with generalized pustular psoriasis, a severe orphan disease that is potentially life-threatening if left untreated.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Vapotherm, Inc., announced first quarter 2024 financial results and related highlights.

Kite, a Gilead Company, and Arcellx, Inc. announced several key operational updates on their partnered anitocabtagene autoleucel multiple myeloma program.

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

DBV Technologies announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May.

BioSyent Inc. will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, 2024 after market hours.